Scarica l'app Stockscreener
4.51
3.68%
0.16
Dopo l'orario di chiusura:
4.57
0.06
+1.33%
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
Price action breakdown for Artelo Biosciences Inc.Quarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Sentiment analysis tools applied to Artelo Biosciences Inc.July 2025 EndofMonth & Pattern Based Trade Signal System - Newser
Published on: 2025-09-06 13:10:32 - Newser
How to use a screener to detect Artelo Biosciences Inc. breakouts2025 Market Sentiment & Daily Profit Focused Screening - Newser
Artelo Biosciences closes $3 million public offering of common stock By Investing.com - Investing.com Canada
Is Artelo Biosciences Inc. a turnaround story2025 Trading Recap & Fast Momentum Stock Entry Tips - خودرو بانک
Artelo Biosciences Closes $3 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq
Artelo Biosciences Announces Closing of $3.0 Million Public Offe - GuruFocus
Artelo Biosciences closes $3 million public offering of common stock - Investing.com
Artelo Biosciences Closes $3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences Announces Closing of $3.0 Million Public Offering - GlobeNewswire
Artelo Biosciences Completes $3 Million Public Offering - AInvest
Clinical-Stage Biotech Artelo Biosciences Secures $3M Through Public Offering at $4.40 Per Share - Stock Titan
Artelo Biosciences 15min Chart Triggers KDJ Golden Cross, Bullish Marubozu Candle - AInvest
Form 424B5 ARTELO BIOSCIENCES, INC. - StreetInsider
Leading vs lagging indicators on Artelo Biosciences Inc. performanceJuly 2025 Reactions & Safe Capital Growth Tips - Newser
Artelo Biosciences Inc. stock trend outlook and recovery path2025 Key Lessons & Consistent Growth Equity Picks - Newser
Ranking Artelo Biosciences Inc. among high performing stocks via toolsProduct Launch & Real-Time Buy Signal Notifications - Newser
Artelo Biosciences prices $3 million public offering of common stock By Investing.com - Investing.com Canada
Artelo Biosciences Raises $3mln Through Common Stock and Warrant Offering - AInvest
Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq
Artelo Biosciences announces pricing of $3 million public offering - MSN
How to read the order book for Artelo Biosciences Inc.Portfolio Return Report & Low Drawdown Trading Strategies - Newser
Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results - Benzinga
Artelo Biosciences Plummets 51%: A Tale of Triumph and Turmoil in Biotech's High-Stakes Arena - AInvest
Artelo Biosciences Plummets 51%: Can Positive Trial Results Salvage Investor Confidence? - AInvest
Artelo Biosciences announces pricing of $3.0 million public offering - MarketScreener
Can Artelo Biosciences Inc. sustain its profitabilityCPI Data & Community Driven Trade Alerts - خودرو بانک
Artelo Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Artelo Biosciences prices $3 million public offering of common stock - Investing.com
Artelo Biosciences Prices $3 Million Offering; Shares Fall 50% Pre-Bell - MarketScreener
Artelo Biosciences Plunges 28.08% on Public Offering Announcement - AInvest
Artelo Biosciences Announces $3M Public Offering of Common Stock and Warrants. - AInvest
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering - GlobeNewswire
$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research - Stock Titan
Artelo Biosciences Launches Public Offering with Undetermined Size and Terms - AInvest
Artelo Biosciences Plunges 14.38% on Public Offering Announcement - AInvest
Custom strategy builders for tracking Artelo Biosciences Inc.July 2025 Opening Moves & Community Consensus Stock Picks - Newser
Building trade automation scripts for Artelo Biosciences Inc.Weekly Stock Summary & Smart Swing Trading Techniques - Newser
What Fibonacci levels say about Artelo Biosciences Inc. reboundTrade Entry Report & Safe Capital Growth Plans - Newser
Will Artelo Biosciences Inc. continue its uptrendAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - Newser
How to interpret RSI for Artelo Biosciences Inc. stockWeekly Profit Report & Safe Entry Point Identification - Newser
Artelo Biosciences reports interim Phase 2 data for cancer cachexia treatment By Investing.com - Investing.com South Africa
Is a relief rally coming for Artelo Biosciences Inc. holdersMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Will Artelo Biosciences Inc. benefit from macro trendsMarket Performance Summary & Technical Confirmation Trade Alerts - Newser
Does Artelo Biosciences Inc. offer margin of safetyJuly 2025 Momentum & Consistent Return Strategy Ideas - khodrobank.com
Artelo Biosciences announces proposed underwritten public offering - MarketScreener
Artelo Biosciences launches public offering of common stock - Investing.com
Artelo Biosciences reports interim Phase 2 data for cancer cachexia treatment - Investing.com
Artelo Biosciences launches public offering; shares down 10% - MSN
Artelo Biosciences Announces Proposed Underwritten Public Offering - The Manila Times
Artelo Biosciences Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants - AInvest
Clinical-Stage Pharma Artelo Biosciences Launches New Public Stock Offering via R.F. Lafferty - Stock Titan
Artelo Biosciences Drug Helps Cancer Patients Regain Weight, Eyes Licensing Deal - Benzinga
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results - The Manila Times
Cancer Wasting Treatment Breakthrough: Artelo's ART27.13 Shows Promise in Phase 2 Trial for 80% of Cancer Patients - Stock Titan
Artelo Biosciences Reports Encouraging Interim Results for ART27.13 in Phase 2 Cancer Appetite Recovery Study, Supporting Weight Gain and Activity Improvements in Cancer Patients - Quiver Quantitative
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) - The Manila Times
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):